

MONT-SAINT-GUIBERT, Belgium, October 7, 2013 /PRNewswire/ --

The Belgian biotechnology company Cardio3 BioSciences (C3BS), a leader in the discovery and development of regenerative, protective and reconstructive therapies for the treatment of cardiac diseases, announces the appointment of Dr. Gaëtane Metz as Chief Operating Officer in view of accelerating the industrialization process and preparing the commercialization of its lead product C-Cure®.

Dr. Metz brings to the Company extensive experience in industry, where she has built experience in Research & Development, medical affairs and operational excellence including automation to increase productivity, management of inspection, integration of production, reorganization and simplification of processes, and transfer products from R&D to commercial manufacturing.

Prior to joining C3BS, Dr. Metz held the position of Managing Director of the Life Sciences, Energy and Industry Division at Altran Europe. Dr. Metz has also held senior and management positions at CVO CyberConseil, and GlaxoSmithKline Biologicals (GSK) where she worked for 11 years. Her work included all aspects and stages of project management, driving the various departments to collaborate and integrate with one another in order to speed up processes and increase efficiency.

Dr. Metz holds a PhD in Bioengineering/Biomedical from the Free University of Brussels (ULB).

Dr. Gaëtane Metz, COO, said: "Cardio3 BioSciences' pipeline holds great therapeutic potential for significant, currently unmet medical needs. I am pleased and excited to have the opportunity to join the Company and lead operations to help the transition of C-Cure® from late clinical

development to a commercial product."

Dr Christian Homsy, CEO of Cardio3 BioSciences, commented: "I am delighted to have Dr Metz join the management team and share her process and industrialization expertise as we prepare for the commercialization of our lead product candidate, C-Cure. Dr Metz's expertise in process development and experience in automation and industrialization will be instrumental in building the systems that will provide the foundations for the launch of C-Cure®."

About Cardio3 BioSciences

Cardio3 BioSciences is a Belgian leading biotechnology company focused on the discovery and development of regenerative and protective therapies for the treatment of cardiac diseases. The company was founded in 2007 and is based in the Walloon region of Belgium. Cardio3 BioSciences leverages research collaborations in the US and in

Europe

with Mayo Clinic and the Cardiovascular Centre Aalst,

Belgium

The Company's lead product candidate C-Cure® is an innovative pharmaceutical product that is being developed for heart failure indication. C-Cure® consists of a patient's own cells that are harvested from the patient's bone marrow and engineered to become new heart muscle cells that behave identically to those lost to heart disease. This process is known as Cardiopoiesis.

Cardio3 BioSciences has also developed C-Cath®_{ez}, the most technologically injection catheter with superior efficiency of delivery of bio therapeutic agents into the myocardium.

Cardio3 BioSciences' shares are listed on NYSE Euronext Brussels and NYSE Euronext Paris under the ticker symbol CARD.

C3BS-CQR-1, C-Cure, C-Cath, Cardio3 BioSciences and the Cardio3 BioSciences and C-Cath logos are trademarks or registered trademarks of Cardio3 BioSciences SA, in Belgium, other

countries, or both. Mayo Clinic holds equity in Cardio3 BioSciences as a result of intellectual property licensed to the company. In addition to historical facts or statements of current condition, this press release contains forward-looking statements, which reflect our current expectations and projections about future events, and involve certain known and unknown risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. These forward-looking statements are further qualified by important factors, which could cause actual results to differ materially from those in the forward-looking statements, including timely submission and approval of anticipated regulatory filings; the successful initiation and completion of required Phase III studies; additional clinical results validating the use of adult autologous stem cells to treat heart failure; satisfaction of regulatory and other requirements; and actions of regulatory bodies and other governmental authorities. As a result, of these factors investors and prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or review any forward-looking statement, whether as a result of new information, future events or otherwise.

For more information contact:

Cardio3 BioSciences Dr Christian Homsy, CEO Anne Portzenheim, Communication Manager [http://
www.c3bs.com](http://www.c3bs.com)
Tel : +32-10-39-41-00
aportzenheim@c3bs.com

Citigate Dewe Rogerson Chris Gardner Tel : +44(0)207-638-9571

SOURCE Cardio3 BioSciences